UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Health-related quality of life scores of metastatic pancreatic cancer patients responsive to first line chemotherapy compared to newly derived EORTC QLQ-C30 reference values

BMC cancer, 2022-05, Vol.22 (1), p.563-563, Article 563

2022

Volltextzugriff (PDF)

Epidemiology, treatment patterns, and humanistic and economic burden of biliary tract carcinoma: A systematic and targeted literature review

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.443-443

2024

Volltextzugriff (PDF)

Abstract P2-08-21: Overall survival associated with BRCA or ATM mutation status in patients with metastatic triple-negative breast cancer: Findings from the PRIOR-2 study

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-08-21

2022

Volltextzugriff (PDF)

Abstract P5-13-11: Patient characteristics and treatment patterns by BRCA/ATM mutation status in patients with metastatic triple-negative breast cancer in the US: An electronic health records (EHR) based study

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-13-11

2022

Volltextzugriff (PDF)

Health outcomes of gBRCA testing strategies for metastatic pancreatic cancer patients

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.537-537

2022

Volltextzugriff (PDF)

Real-world neo-adjuvant with or without adjuvant treatment patterns among pancreatic ductal adenocarcinoma patients in the U.S

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e16217-e16217

2021

Volltextzugriff (PDF)

Real-world timelines of BRCA1/2-related molecular testing in pancreatic cancer

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.601-601

2022

Volltextzugriff (PDF)

Real-world use of PARP inhibitors in BRCA1/2-mutated pancreatic cancer: A retrospective analysis

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.599-599

2022

Volltextzugriff (PDF)

Modeling health outcomes associated with BRCA testing and treatment strategies for patients with metastatic pancreatic cancer

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2024-03, Vol.24 (2), p.271-278

2024

Volltextzugriff (PDF)

Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer’s Perspective

PharmacoEconomics, 2022-12, Vol.40 (12), p.1247-1259

2022

Volltextzugriff (PDF)

Adjuvant and neoadjuvant treatment patterns among resectable pancreatic cancer patients in the USA

Future oncology (London, England), 2022-11, Vol.18 (35), p.3929-3939

2022

Volltextzugriff (PDF)

Patient‐centered outcomes in the POLO study of active maintenance olaparib for germline BRCA‐mutated metastatic pancreatic cancer

Cancer, 2023-05, Vol.129 (9), p.1411-1418

2023

Volltextzugriff (PDF)

Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck

Future oncology (London, England), 2019-03, Vol.15 (7), p.739-751

2019

Volltextzugriff (PDF)

Reference values for EORTC QLQ-C30, for metastatic pancreatic cancer (mPC): Enhancing the interpretation of HRQoL scores in the POLO trial

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.393-393

2021

Volltextzugriff (PDF)

Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer

The oncologist (Dayton, Ohio), 2024-05, Vol.29 (10), p.e1324-e1335

2024

Volltextzugriff (PDF)

Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study

Oral oncology, 2020-03, Vol.102, p.104526-104526, Article 104526

2020

Volltextzugriff (PDF)

POLO: Quality-adjusted (QA) progression-free survival (PFS) and patient (pt)-centered outcomes with maintenance olaparib in pts with metastatic pancreatic cancer (mPaC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4626-4626

2020

Volltextzugriff (PDF)

Treatment patterns in recurrent/metastatic head and neck squamous cell carcinoma in the US

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.6033-6033

2017

Volltextzugriff (PDF)

Global longitudinal assessment of treatment outcomes in recurrent/metastatic nasopharyngeal carcinoma: GLANCE-NPC study

Future oncology (London, England), 2021-06, Vol.17 (16), p.2015-2025

2021

Volltextzugriff (PDF)

Abstract 4871: Colorectal cancer incidence and overall survival by race, stage, and age: A SEER database analysis, 2009-2020

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.4871-4871

2024

Volltextzugriff (PDF)

Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (g BRCA m): Phase III POLO trial

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.648-648

2020

Volltextzugriff (PDF)

Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data

Arthritis care & research (2010), 2016-03, Vol.68 (3), p.308-317

2016

Volltextzugriff (PDF)

Health-Related Quality of Life of Patients with Metastatic Pancreatic Cancer: A Systematic Literature Review

Cancer management and research, 2022-01, Vol.14, p.3383-3403

2022

Volltextzugriff (PDF)

Prevalence of Exposure to Potential CYP450 Pharmacokinetic Drug-Drug Interactions among Patients with Chronic Low Back Pain Taking Opioids

Pain practice, 2011-05, Vol.11 (3), p.230-239

2011

Volltextzugriff (PDF)

Exposure to Potential CYP450 Pharmacokinetic Drug-Drug Interactions among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions

Pain practice, 2011-07, Vol.11 (4), p.325-336

2011

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(26)
Dissertationen
(1)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Health-related quality of life scores of metastatic pancreatic cancer patients responsive to first line chemotherapy compared to newly derived EORTC QLQ-C30 reference values

Epidemiology, treatment patterns, and humanistic and economic burden of biliary tract carcinoma: A systematic and targeted literature review

Abstract P2-08-21: Overall survival associated with BRCA or ATM mutation status in patients with metastatic triple-negative breast cancer: Findings from the PRIOR-2 study

Abstract P5-13-11: Patient characteristics and treatment patterns by BRCA/ATM mutation status in patients with metastatic triple-negative breast cancer in the US: An electronic health records (EHR) based study

Health outcomes of gBRCA testing strategies for metastatic pancreatic cancer patients

Real-world neo-adjuvant with or without adjuvant treatment patterns among pancreatic ductal adenocarcinoma patients in the U.S

Real-world timelines of BRCA1/2-related molecular testing in pancreatic cancer

Real-world use of PARP inhibitors in BRCA1/2-mutated pancreatic cancer: A retrospective analysis

Modeling health outcomes associated with BRCA testing and treatment strategies for patients with metastatic pancreatic cancer

Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer’s Perspective

Adjuvant and neoadjuvant treatment patterns among resectable pancreatic cancer patients in the USA

Patient‐centered outcomes in the POLO study of active maintenance olaparib for germline BRCA‐mutated metastatic pancreatic cancer

Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck

Reference values for EORTC QLQ-C30, for metastatic pancreatic cancer (mPC): Enhancing the interpretation of HRQoL scores in the POLO trial

Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer

Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study

POLO: Quality-adjusted (QA) progression-free survival (PFS) and patient (pt)-centered outcomes with maintenance olaparib in pts with metastatic pancreatic cancer (mPaC)

Treatment patterns in recurrent/metastatic head and neck squamous cell carcinoma in the US

Global longitudinal assessment of treatment outcomes in recurrent/metastatic nasopharyngeal carcinoma: GLANCE-NPC study

Abstract 4871: Colorectal cancer incidence and overall survival by race, stage, and age: A SEER database analysis, 2009-2020

Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (g BRCA m): Phase III POLO trial

Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data

Health-Related Quality of Life of Patients with Metastatic Pancreatic Cancer: A Systematic Literature Review

Prevalence of Exposure to Potential CYP450 Pharmacokinetic Drug-Drug Interactions among Patients with Chronic Low Back Pain Taking Opioids

Exposure to Potential CYP450 Pharmacokinetic Drug-Drug Interactions among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions

Suchergebnisse filtern